SVRA Savara (SVRA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001160308
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
92
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $1.0M priced
What the filings say about SVRA
Insiders, 180 days
-$2.2M net sold
1 seller · 0% of sales under a 10b5-1 plan
Savara insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Savara Inc insiders sold a net $2.2M of stock across 86 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (1 buy, 2 sales), the last on Dec 16, 2024.
- The trade is 73.6% of the 536,032 shares held after it.
- No other insider sold within 30 days.
- 92 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Lowrance David L sold about $2.2M of SVRA on Jun 22, 2026, the largest insider sale at the company on our record; 92 funds added in the latest 13F quarter.Context
- 54 earlier Form 4 trades (code P or S) here by this insider (54 buys), the last on Mar 31, 2025.
- +29.7% median (+31.9% mean) 90-day return after 30 previous buys.
- The trade is 0.8% of the 2,533,642 shares held after it.
- No other insider sold within 30 days.
- 92 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RAMSAY DAVID A sold about $121.2K of SVRA on Dec 19, 2025, the largest insider sale at the company since 2024; 92 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Dec 16, 2024.
- The trade is 41.8% of the 115,466 shares held after it.
- 1 other insider bought within 30 days.
- 92 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Hawkins Richard J bought about $98.4K of SVRA on Jun 20, 2025; 1 other insider bought within 30 days and 92 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Nov 19, 2024.
- The trade is 3.8% of the 260,837 shares held after it.
- 1 other insider bought within 30 days.
- 92 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director McCracken Joseph S bought about $20.8K of SVRA on May 29, 2025; 1 other insider bought within 30 days and 92 funds added in the latest 13F quarter.Context
- 53 earlier Form 4 trades (code P or S) here by this insider (53 buys), the last on Nov 18, 2024.
- +29.7% median (+32.5% mean) 90-day return after 30 previous buys.
- The trade is 6.0% of the 2,513,642 shares held after it.
- No other insider bought within 30 days.
- 92 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RAMSAY DAVID A bought about $417.0K of SVRA on Mar 31, 2025, the largest insider purchase at the company since 2023; 92 funds added in the latest 13F quarter.86 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$2.2M over 180 days
below 72% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
92 funds bought in last quarter
more than 65% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
22.1% of the float short (float per yahoo 2026-10-27) · 12.2 days to cover · settled 2026-10-15
more than 83% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch SVRA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+9.7%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns SVRA: institutional holders (13F)
13F holdings, latest reported quarter
24,471,264 sh
$150.7M
17,600,621 sh
$108.4M
14,745,943 sh
$90.8M
13,953,620 sh
$86.0M
13,569,000 sh
$83.6M
Congress trades in SVRA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
SVRA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Lowrance David L
Filed 2026-06-22
$2.2M
SVRA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
F/m Emerald Life Sciences Innovation ETF
$3.4M position · as of 2026-05-31
3.2%
Virtus Biotech Clinical Trials Etf
$322.6K position · as of 2026-07-31
0.7%
VOYA SMALL COMPANY PORTFOLIO
$1.5M position · as of 2026-06-30
0.7%
Janus Henderson Small Cap Growth Alpha ETF
$2.2M position · as of 2026-07-31
0.6%
Voya MI Dynamic Small Cap Fund
$1.1M position · as of 2026-05-31
0.6%
Emerald Growth Fund
$4.4M position · as of 2026-07-31
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
7 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 2
0 active
3
Phase 3
2 active
1
Not applicable
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Mr. Pauls
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$4.8M
$9.9M
$2.4M
+96%
n/a
2024
$4.9M
$4.0M
$1.9M
-35%
n/a
2023
$3.8M
$5.7M
$2.1M
+203%
n/a
2022
$2.2M
$2.5M
$876.4K
+25%
n/a
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $2.2M sold by insiders over 180 days, 92 funds added last quarter. Each figure is a federal filing, dated the day it went public.
SVRA financials
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM SVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM SVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$110.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM SVRA
| FY Dec 2025 | -$101.1M |
| FY Dec 2024 | -$89.1M |
| FY Dec 2023 | -$51.4M |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -$30.0M |
| Mar 2026 | -$33.1M |
| Dec 2025 | -$25.1M |
| Sep 2025 | -$22.5M |
| Jun 2025 | -$26.3M |
| Mar 2025 | -$27.2M |
| Dec 2024 | -$23.3M |
| Sep 2024 | -$22.7M |
At each fiscal year end
Single quarter
Debt to equity
0.21x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity SVRA
| FY Dec 2025 | 0.15x |
| FY Dec 2024 | 0.16x |
| FY Dec 2023 | 0.28x |
| FY Dec 2022 | 0.36x |
| FY Dec 2021 | 0.18x |
| Jun 2026 | 0.21x |
| Mar 2026 | 0.17x |
| Dec 2025 | 0.15x |
| Sep 2025 | 0.32x |
| Jun 2025 | 0.25x |
| Mar 2025 | 0.20x |
| Dec 2024 | 0.16x |
| Sep 2024 | 0.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-3.67x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt SVRA
| FY Dec 2025 | -3.38x |
| FY Dec 2024 | -3.35x |
| FY Dec 2023 | -1.31x |
| FY Dec 2022 | -0.90x |
| FY Dec 2021 | -1.56x |
| Jun 2026 | -3.67x |
| Mar 2026 | -3.56x |
| Dec 2025 | -3.38x |
| Sep 2025 | -3.33x |
| Jun 2025 | -3.35x |
| Mar 2025 | -3.24x |
| Dec 2024 | -3.35x |
| Sep 2024 | -2.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-105.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity SVRA
| FY Dec 2025 | -63.5% |
| FY Dec 2024 | -61.5% |
| FY Dec 2023 | -44.1% |
| FY Dec 2022 | -30.2% |
| FY Dec 2021 | -41.2% |
| Jun 2026 | -105.5% |
| Mar 2026 | -80.0% |
| Dec 2025 | -63.5% |
| Sep 2025 | -78.7% |
| Jun 2025 | -99.3% |
| Mar 2025 | -75.8% |
| Dec 2024 | -61.5% |
| Sep 2024 | -48.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-78.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets SVRA
| FY Dec 2025 | -51.0% |
| FY Dec 2024 | -49.1% |
| FY Dec 2023 | -34.5% |
| FY Dec 2022 | -24.1% |
| FY Dec 2021 | -31.4% |
| Jun 2026 | -78.3% |
| Mar 2026 | -63.0% |
| Dec 2025 | -51.0% |
| Sep 2025 | -60.9% |
| Jun 2025 | -72.7% |
| Mar 2025 | -58.8% |
| Dec 2024 | -49.1% |
| Sep 2024 | -39.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital SVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-88.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed SVRA
| FY Dec 2025 | -57.3% |
| FY Dec 2024 | -56.5% |
| FY Dec 2023 | -39.9% |
| FY Dec 2022 | -26.3% |
| FY Dec 2021 | -33.0% |
| Jun 2026 | -88.5% |
| Mar 2026 | -69.9% |
| Dec 2025 | -57.3% |
| Sep 2025 | -69.3% |
| Jun 2025 | -84.3% |
| Mar 2025 | -67.0% |
| Dec 2024 | -56.5% |
| Sep 2024 | -44.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing SVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$917.0M
market value at close 2026-10-26 on 2026-08-11 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value SVRA
| FY Dec 2025 | $1.2B |
| FY Dec 2024 | $538.4M |
| FY Dec 2023 | $648.4M |
| FY Dec 2022 | $163.2M |
| FY Dec 2021 | $132.8M |
| Jun 2026 | $1.3B |
| Mar 2026 | $1.1B |
| Dec 2025 | $1.2B |
| Sep 2025 | $630.5M |
| Jun 2025 | $406.3M |
| Mar 2025 | $488.2M |
| Dec 2024 | $538.4M |
| Sep 2024 | $715.5M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-11.9%
TTM free cash flow over market value at close 2026-10-26
FCF yield SVRA
| FY Dec 2025 | -8.2% |
| FY Dec 2024 | -16.9% |
| FY Dec 2023 | -8.1% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -8.8% |
| Mar 2026 | -9.6% |
| Dec 2025 | -8.2% |
| Sep 2025 | -16.1% |
| Jun 2025 | -25.2% |
| Mar 2025 | -20.0% |
| Dec 2024 | -16.9% |
| Sep 2024 | -11.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing SVRA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Operating income | -$123.5M | -$103.2M | -$60.0M | -$38.8M |
| Net income | -$118.8M | -$95.9M | -$54.7M | -$38.1M |
| EPS (diluted) | -0.53 | -0.48 | -0.33 | -0.25 |
| Operating cash flow | -$101.0M | -$89.1M | -$51.1M | -$34.6M |
| Cash | $33.2M | $15.1M | $26.6M | $52.1M |
| Long-term debt | $29.9M | $26.6M | $26.3M | $26.1M |
SEC XBRL, fiscal years, as known on 2026-10-28
SVRA Stock Sonar score 5/7 axes
Find similar shapesCompareSVRA ranks highest on institutional and government (48th percentile) and risk and compliance (41st), and lowest on insider conviction (14th), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
SVRA filings, in plain words
Are Savara insiders buying or selling SVRA?
In the 180 days to 2026-10-28, Savara insiders were net sellers, a net $2.2M across purchases and sales reported on Form 4, by 1 seller.
Read the full summary
In the 180 days to 2026-10-28, Savara insiders were net sellers of SVRA, a net $2.2M across purchases and sales reported on Form 4 by 1 seller. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
